AstraZeneca ticks another box as U.S. approves severe asthma drug

LONDON (Reuters) - AstraZeneca has achieved another milestone in rebuilding its drug portfolio with U.S. approval of a drug for severe asthma as the company battles to put patent losses on older medicines behind it.